Nypozi (filgrastim)

pCPA File Number: 21891

Negotiation Status:

Concluded with an LOI

Indication(s):

Neutropenia in various indications (Prevention or treatment)

Sponsor/Manufacturer:

Tanvex BioPharma USA, Inc.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2022-12-15

Negotiation Process Concluded:

2023-03-10